Vyvron, Checked but Not Graded: Thirteen Charges a Year, and No Monthly Tirzepatide

This investigation records the Vyvron (vyvron.com) pages reviewed on August 7, 2026. Prices, policies, clinical disclosures, testimonials and the enrollment counter below are historical observations, not a current merchant check. Two of the three weight-loss tiers recorded then were prepaid plans, and the recurring tier billed every four weeks. This page has no WeighScore or ranking position. Our methodology explains the separate grading framework.

The unit is not a month

The reviewed weight-loss page quoted $199 per four weeks, billed every four weeks, auto-renewing until you cancel. Elsewhere on the same site, that plan was described as treatment from $199 a month.

Four weeks is not a month. A four-week cycle bills 13 times in a year, not 12. At the $199 rung that is $2,587 a year rather than the $2,388 a reader doing the obvious multiplication would arrive at — a $199 difference not separately presented on the reviewed pages, because the extra charge is not a fee, it is a thirteenth month that the calendar does not have. This is precisely the failure mode what compounded GLP-1 costs per month is about: the cadence, not the sticker, is where an offer quietly changes size.

Tirzepatide required prepayment

The August review recorded three weight-loss tiers, with recurring billing only on the semaglutide plan.

The Start tier was semaglutide only at $199 per four weeks. The tirzepatide Transform tier displayed $285 a month but required $790 paid once for twelve weeks. Premium displayed $248 a month but required $2,981 paid once for a year. The lowest recorded tirzepatide entry payment was therefore $790; no single-month option was found.

Those prepaid offers did not establish a monthly tirzepatide purchase price. Compare the full commitment, rather than treating a monthly equivalent as a payment option.

The displayed "$285 a month" divided $790 across roughly 2.77 calendar months. Dividing $790 across the three four-week cycles instead gives about $263. The same pricing table used two different definitions of "per month".

Founding rates, and which page to believe

The August program pages advertised founding rates: weight loss at $199 per four weeks against a list price of $249, microdosing at $149 against $179, longevity at $189 against $229. The homepage cards disagreed — showing $179 for microdosing, which is the post-founding list price presented as though it were current, and $145 for longevity, which is the cheapest individual longevity item rather than the program rate.

The August comparison used the program pages because they carried enrollment buttons and billing disclosures. Individual longevity listings were injectable NAD+ at $229, injectable sermorelin at $229, and injectable B12-MIC at $145.

The August page displayed 100 of 100 founding-member spots remaining, with a full progress bar. The reviewed display used a fixed value rather than a verified live enrollment count. That observation does not establish enrollment numbers or whether the counter would change in a later version.

The named clinical network

The August privacy disclosure named OpenLoop Health, Inc. and its affiliated professional entities. The named group provides a starting point for identity research; it does not establish the clinician assigned to an individual patient or the quality of care.

The reviewed pages advertised all 50 states and the District of Columbia, with video visits required in Arkansas, DC, Delaware, Kansas, Mississippi, New Mexico, Rhode Island and West Virginia. They separately excluded compounded GLP-1 in Mississippi. Product restrictions therefore mattered alongside the broad coverage claim. For comparison, the August Auren Rx investigation found no published state list.

What is missing under it

The reviewed pages did not name a dispensing pharmacy or individual prescriber. The OpenLoop organization name can support a registry search even without a published NPI, but this investigation did not establish an exact organization match or the assigned clinician's identity. An NPI is not proof of licensure or credentials; a state-board license check is separate. The pages identified Vyvron, LLC, at 30 N Gould St in Sheridan, Wyoming — an address shared by an enormous number of companies, and not an operating location. The assigned pharmacy and clinician remained questions to resolve.

The August testimonial section contained placeholder text saying patient stories would appear after founding members gave written consent. That does not establish how many patients enrolled or completed treatment. This investigation did not independently establish long-term patient experience; weight regain after stopping GLP-1 explains why follow-up beyond an initial purchase matters.

Terms, and the 72-hour window

The August terms described payment at intake, before clinical review. They offered a full refund for cancellation within 72 hours if no services had been rendered, or for medical disqualification. Ongoing-plan cancellation required 72 hours' notice before the next billing date to avoid that cycle's charge. On prepaid Transform and Premium plans, refunds covered only months whose medication had not shipped.

Read together with the four-week cycle, that means the billing date you have to track is not the same date each month, and it moves earlier through the calendar year.

The regulatory screen

The FDA's live warning-letter index returned no company-column match in August 2026 for Vyvron or for OpenLoop. The same pass returned a known February 2026 letter for an unrelated telehealth seller run as a positive control, so the zeros are evidence rather than a query that failed quietly.

Where it sits

The August observations raised questions about billing cadence, prepaid tirzepatide, conflicting headline prices, dispensing identity and unverified patient experience. Those questions do not establish treatment quality or patient numbers. This historical investigation remains ungraded and does not place Vyvron on the cheapest GLP-1 ledger or the tirzepatide ranking. If you are shopping it anyway, the questions worth asking first are in our six-point checklist.